Lissette Selem, MD
Psychiatry · Miami Lakes, FLNPI 1093910499
Payments from drug & device makers
Across 930 payments — averaging $1676.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$771K
- Janssen Research & Development, LLC$385K
- Jazz Pharmaceuticals Inc.$129K
- Eli Lilly$114K
- Acadia Pharmaceuticals Inc$105K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
- plus $34K from 21 others
Across 1 payment — averaging $57,167 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$57K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 237 | $771,118 |
| Janssen Research & Development, LLC | 39 | $385,226 |
| Jazz Pharmaceuticals Inc. | 7 | $128,976 |
| Eli Lilly | 5 | $114,056 |
| Acadia Pharmaceuticals Inc | 27 | $105,054 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $20,396 |
| Avanir Pharmaceuticals, Inc. | 5 | $14,097 |
| Sumitomo Pharma America, Inc. | 15 | $7,336 |
| Teva Pharmaceuticals USA, Inc. | 123 | $2,448 |
| AbbVie(2 entities) | 124 | $2,249 |
| Sunovion Pharmaceuticals Inc. | 117 | $2,035 |
| Otsuka America Pharmaceutical, Inc. | 85 | $1,576 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $889 |
| Neurocrine Biosciences, Inc. | 30 | $732 |
| Lundbeck LLC | 25 | $538 |
| Vanda Pharmaceuticals Inc. | 24 | $516 |
| Alkermes, Inc. | 23 | $500 |
| Axsome Therapeutics, Inc. | 12 | $320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $241 |
| E.r. Squibb & Sons, L.L.C. | 6 | $167 |
| Johnson & Johnson | 4 | $74 |
| Tris Pharma Inc | 3 | $73 |
| Almatica Pharma LLC | 2 | $48 |
| Noven Therapeutics, LLC | 2 | $36 |
| Tempus AI, Inc | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
How this compares
$1,558,770 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Miami Lakes
- Lourdes SelemMiami Lakes$5.4M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.